Decibel Therapeutics, Inc.

NasdaqGS:DBTX Stock Report

Market Cap: US$124.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Decibel Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Decibel Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.3%

Buyback Yield

Total Shareholder Yield-0.3%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Aug 10

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 07

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 17

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

The U.S. Food and Drug Administration (FDA) granted clearance to Decibel Therapeutics' (NASDAQ:DBTX) investigational new drug (IND) application for starting a phase 1/2 trial of gene therapy DB-OTO to treat hearing loss in pediatric patients. DB-OTO is aimed to provide durable hearing in individuals born with profound congenital hearing loss due to deficiency of a protein called otoferlin, according to the company. Decibel said DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) and is an adeno-associated virus (AAV)-based gene therapy product candidate. The company added that a one-time administration of DB-OTO had shown a production of otoferlin protein and durable auditory brainstem responses to sound in a congenitally deaf rodent disease model. Decibel expects the first two participants in the U.S. portion of the phase 1/2 trial will be as young as seven years of age and afterwards will include children as young as two years of age, and infants below two years of age. The company noted that DB-OTO is the second product candidate after DB-020 in its pipeline to advance into clinical testing. DBTX +18.24% to $3.50 premarket Oct. 17
Analysis Article • Sep 01

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 06

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel is a category leader in developing new medicines for hearing and balance disorders. The company's lead asset, DB-OTO, has several upcoming catalysts over the next 18 months that can validate Decibel's platform. With a unique business model, Decibel is a compelling investment positioned to rapidly expand their pipeline and partnerships pending DB-OTO.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if DBTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DBTX's dividend payments have been increasing.

Dividend Yield vs Market

Decibel Therapeutics Dividend Yield vs Market
How does DBTX dividend yield compare to the market?
SegmentDividend Yield
Company (DBTX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.2%
Analyst forecast (DBTX) (up to 3 years)0%

Notable Dividend: Unable to evaluate DBTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DBTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate DBTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DBTX has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/06 17:13
End of Day Share Price 2023/09/22 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Decibel Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Matthew LuchiniBMO Capital Markets Equity Research